TIDMAKR

RNS Number : 1435P

Akers Biosciences, Inc.

05 February 2019

February 5, 2019

Akers Biosciences, Inc.

Further Re. Directorate Change

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that, further to the announcement dated September 13, 2018 concerning the appointment of Joshua Silverman as a director of the Company, the Company's Nominated Adviser has completed its necessary due diligence.

Accordingly, the following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Full name: Joshua Nathaniel Silverman

Age: 48

Current directorships/partnerships: DropCar, Inc., Protagenic Therapeutics, Inc, Neurotrope, Inc, Parkfield Funding LLC, SM Capital Management LLC, JNS Holdings Corporation

Past directorships/partnerships (past 5 years): National Holdings Corporation, MGT Capital Investments Inc, Alanco Technologies, Inc, TapImmune, Inc., Iroquois Capital Management, LLC.

Mr. Silverman was appointed as a director of the Company with effect from September 6, 2018 and is a member of the Company's audit committee, compensation committee and nominating and corporate governance committee.

Mr. Silverman does not have any interest in the shares of Akers Bio.

Inquiries:

Akers Biosciences, Inc.

Howard R. Yeaton, Chief Executive Officer and Interim Chief Financial Officer

Tel. +1 856 848 8698

finnCap (UK Nominated Adviser and Broker)

Ed Frisby / Scott Mathieson (Corporate Finance)

Tel. +44 (0)20 7220 0500

Vigo Communications (Global Public Relations)

Ben Simons / Fiona Henson

Tel. +44 (0)20 7390 0234

Email: akers@vigocomms.com

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com.

Cautionary Note Regarding Forward-Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, compliance with the requirements of various regulatory agencies and certain NASDAQ Stock Market listing rules, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should, " "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions, as they relate to the Company, its subsidiaries, or its management. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, performance, prospects, and opportunities to may differ materially from those set forth in, or implied by, the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAKMGGZZKMGLZM

(END) Dow Jones Newswires

February 05, 2019 08:00 ET (13:00 GMT)

Akers Biosciences (LSE:AKR)
Historical Stock Chart
Von Jan 2025 bis Feb 2025 Click Here for more Akers Biosciences Charts.
Akers Biosciences (LSE:AKR)
Historical Stock Chart
Von Feb 2024 bis Feb 2025 Click Here for more Akers Biosciences Charts.